Q-omics provides the consensus-scored CRX profile across patient tissues and cancer cell-line models. CRX expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CRX is differentially expressed in 2, with the highest sampling consensus in KICH. Additionally, CRX RNA expression shows 8,506 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where CRX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRX survival associations across molecular data types. CRX RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRX RNA expression–survival associations across cancer types. High CRX expression shows unfavorable associations in KIRC, ACC, KICH, MESO and THCA, but favorable associations in LAML. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CRX RNA expression.
This table summarizes CRX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CRX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRX shows lower tumor expression in KICH and higher tumor expression in KIRC. The KICH box plot shows higher CRX RNA expression in normal versus tumor tissue (log2 FC = −0.013, t-test p = .016).
This table shows molecular features associated with CRX in patient tissues and cancer cell lines. In patient samples, CRX shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CRX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and OVARY.
